| All Releases |
|---|
 |
Pharmos Announces Dosing of First Patients in Clinical Trial of Levotofisopam for the Treatment of Gout
Jan 10, 2012
|
11.8 KB
|
| |
ISELIN, N.J., Jan. 10, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) announced today the dosing of the first patients in the US using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and th...
|
|
|
Pharmos Corporation Reports 2011 Third Quarter Results
Oct 31, 2011
|
15.7 KB
|
| |
ISELIN, N.J., Oct. 31, 2011 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2011. These results are included in the Company's Quarterly Report on Form 10-Q which has been filed with the SEC.
Third Quarter Ended September 30, 2011
The Company ...
|
|
|
Pharmos Corporation Reports 2011 Second Quarter Results
Aug 8, 2011
|
15.8 KB
|
| |
ISELIN, N.J., Aug. 8, 2011 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the second quarter and six-month period ended June 30, 2011. These results are included in the Company's Quarterly Report on Form 10-Q which has been filed with the SEC.
Second Quarter Ended June 30, 2011
The Company recorded a...
|
|
|
Pharmos Corporation Reports First Quarter 2011 Results
Apr 28, 2011
|
12.5 KB
|
| |
ISELIN, N.J., April 28, 2011 /PRNewswire/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the first quarter ended March 31, 2011. The Company recorded a net loss of $0.6 million, or $0.01 per share, for the first quarter 2011 compared to a net loss of $0.5 million, or $0.01 per share, in the first quarter 2010.
...
|
|
|
Pharmos Corporation Reports Fourth Quarter and Full Year 2010 Results
Feb 17, 2011
|
16.7 KB
|
| |
ISELIN, N.J., Feb. 17, 2011 /PRNewswire/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2010. T...
|
|
|
Pharmos Corporation Reports 2010 Third Quarter Results
Oct 27, 2010
|
14.5 KB
|
| |
ISELIN, N.J., Oct 27, 2010 /PRNewswire via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q which has been filed with the SEC.
During the quarter the Company...
|
|
|
Pharmos Corporation Reports 2010 Second Quarter Results
Aug 4, 2010
|
14.0 KB
|
| |
ISELIN, N.J., Aug 04, 2010 /PRNewswire via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the second quarter and six-month period ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q which has been filed with the SEC.
During the quarter the Company kept...
|
|
|
Pharmos Corporation Reports First Quarter 2010 Results
May 12, 2010
|
11.8 KB
|
| |
ISELIN, N.J., May 12, 2010 /PRNewswire via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the first quarter ended March 31, 2010. The Company recorded a net loss of $0.5 million, or $0.01 per share, for the first quarter 2010 compared to a net loss of $3.7 million, or $0.14 per share, in the fir...
|
|
|
Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
Feb 22, 2010
|
15.8 KB
|
| |
ISELIN, N.J., Feb 22, 2010 /PRNewswire via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2009.
Fourth Quarter Ended December 31, 2009
Pharmos has no revenues at this time. The fourth quarter net income is partly due to a renegotia...
|
|
|
Pharmos Corporation Reports 2009 Third Quarter Results
Nov 12, 2009
|
17.9 KB
|
| |
ISELIN, N.J., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2009.
Third Quarter Ended September 30, 2009The Company recorded a net loss of $1.4 million, or $0.02 per share, for the third quarter ...
|
|
|
Pharmos Corporation Engages Cowen to Assist the Company with Accelerating a Partnership for Dextofisopam
Oct 21, 2009
|
9.2 KB
|
| |
ISELIN, N.J., Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome. While the results did not achieve ...
|
|
|
Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study
Sep 14, 2009
|
11.2 KB
|
| |
Iselin, NJ, September 14, 2009 - Pharmos Corporation (OTCBB - PARS.PK) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.
Although the primary efficacy variable (% of weeks responding for adequate overall relief of IBS symptoms) did n...
|
|
|
Pharmos Corporation Reports 2009 Second Quarter Results
Aug 12, 2009
|
71.4 KB
|
| |
Iselin, NJ, August 12, 2009 - Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2009.
Second Quarter Ended June 30, 2009
The Company recorded a net loss of $2.3 million, or $0.05 per share, for the second quarter 2009 compared to a net loss ...
|
|
|
Pharmos Corporation Reports 2009 First Quarter Results
May 12, 2009
|
49.2 KB
|
| |
Iselin, NJ, May 12, 2009 - Pharmos Corporation (OTCBB - PARS.PK) today reported results for the first quarter ended March 31, 2009. The Company recorded a net loss of $3.7 million, or $0.14 per share, for the first quarter 2009 compared to a net loss of $3.6 million, or $0.14 per share, in the first quarter 2008. Cash and short-term inves...
|
|
|
Pharmos Completes Private Placement - Raises $1.8 Million
Apr 21, 2009
|
9.7 KB
|
| |
Iselin, NJ, April 21, 2009 - Pharmos Corporation (OTCBB - PARS.PK) announced today that it has completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,8...
|
|
|
Pharmos Issues Business Update on Dextofisopam Trial and Financing
Apr 2, 2009
|
9.5 KB
|
| |
Iselin, NJ, April 2, 2009 - Pharmos Corporation (OTCBB - PARS.PK) issued the following business update on the Dextofisopam Phase 2b trial and the status of financing operations.
Dextofisopam Phase 2b trial
As previously announced on March 4, 2009, Pharmos modified the size of the Dextofisopam Phase 2b trial for I...
|
|
|
Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination Company Also Receives Going Concern Audit Opinion
Mar 6, 2009
|
9.8 KB
|
| |
Iselin, NJ, March 6, 2009 Pharmos Corporation (Nasdaq: PARS) announced today that it has received a Nasdaq Staff Determination that the company is not in compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. Unless the company appeals the determination, its securities will be removed from listing a...
|
|
|
Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
Mar 4, 2009
|
10.7 KB
|
| |
ISELIN, N.J., March 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has completed a reevaluation of the size of the Phase 2b Dextofisopam trial for Irritable Bowel Syndrome IBS -D + A and has concluded that a smaller trial could achieve the objectives of the trial. As the Phase 2...
|
|
|
Pharmos Corporation Reports 2008 Fourth Quarter Results
Feb 27, 2009
|
14.4 KB
|
| |
ISELIN, N.J., Feb 27, 2009 /PRNewswire via COMTEX News Network/ -- ISELIN, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2008.
Fourth Quarter Ended December 31, 2008
The Company recorded a net loss of $1.0 million, or $0...
|
|
|
Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists
Feb 18, 2009
|
9.4 KB
|
| |
ISELIN, N.J., Feb 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has entered into an agreement with an Israel based company, Reperio Pharmaceuticals Ltd. (Reperio) for the sale of the patent rights and technical know how related to the compound known as PRS-639,058 and some foll...
|
|
|
